What are the recommended antibiotic regimens for cellulitis in adults, including first‑line oral therapy, options for MRSA risk, and intravenous treatment for severe infection?

Antibiotic Treatment for Cellulitis in Adults

For uncomplicated nonpurulent cellulitis, treat with oral beta-lactams targeting streptococci (cephalexin 500 mg four times daily or amoxicillin 500 mg three times daily) for 5-10 days, reserving MRSA coverage only for treatment failures or specific high-risk scenarios. 1

Clinical Classification Determines Antibiotic Selection

The IDSA guidelines distinguish between two critical cellulitis phenotypes that guide empirical therapy 1:

Nonpurulent Cellulitis (Most Common)

• Presentation: Erythema, warmth, swelling, tenderness WITHOUT purulent drainage or abscess 1
• Primary pathogens: Beta-hemolytic streptococci (Group A Streptococcus) and methicillin-sensitive S. aureus 2, 3
• First-line oral therapy: Beta-lactams such as cephalexin 500 mg PO four times daily or dicloxacillin 500 mg PO four times daily 1
• Duration: 5 days is sufficient, extending only if no improvement 1, 4

Purulent Cellulitis

• Presentation: Cellulitis WITH purulent drainage or exudate but no drainable abscess 1
• Primary pathogen: Community-acquired MRSA (CA-MRSA) 1, 5
• Empirical streptococcal coverage is likely unnecessary in purulent cellulitis 1

Oral Antibiotic Options for MRSA Coverage

When MRSA coverage is indicated, multiple oral options exist 1:

• Clindamycin 300-450 mg PO three times daily (covers both MRSA and streptococci) 1
• Trimethoprim-sulfamethoxazole (TMP-SMX) 1-2 double-strength tablets PO twice daily 1
• Doxycycline 100 mg PO twice daily 1
• Minocycline 200 mg loading dose, then 100 mg PO twice daily 1
• Linezolid 600 mg PO twice daily (more expensive alternative) 1

Important caveat: TMP-SMX and tetracyclines lack reliable streptococcal coverage 1. If dual coverage is needed, combine TMP-SMX or a tetracycline with amoxicillin, or use clindamycin or linezolid alone 1.

When to Add MRSA Coverage

MRSA coverage should be considered in specific scenarios 1:

• Treatment failure after 48-72 hours of beta-lactam therapy 1
• Systemic toxicity or SIRS criteria present 1
• High-risk populations: injection drug users, athletes, prisoners, military recruits, long-term care residents, prior MRSA infection 3, 5
• Penetrating trauma or evidence of MRSA colonization 1

A 2010 study from Hawaii (high CA-MRSA prevalence area) demonstrated TMP-SMX had 91% treatment success versus 74% for cephalexin, with MRSA recovered in 62% of positive cultures 5. However, this reflects a specific geographic context and should not override guideline recommendations for typical nonpurulent cellulitis.

Intravenous Therapy for Severe/Complicated Cellulitis

Hospitalization and IV antibiotics are indicated for 1:

• Complicated SSTI: Deeper infections, surgical/traumatic wounds, major abscesses, infected ulcers/burns 1
• Systemic signs: SIRS, hemodynamic instability, altered mental status 1
• Immunocompromised patients or severe comorbidities 1

IV Antibiotic Options (7-14 days duration) 1:

• Vancomycin 15-20 mg/kg/dose IV every 8-12 hours (first-line) 1
• Linezolid 600 mg IV/PO twice daily 1
• Daptomycin 4 mg/kg/dose IV once daily 1
• Telavancin 10 mg/kg/dose IV once daily 1
• Clindamycin 600 mg IV/PO three times daily (if local resistance <10%) 1

For hospitalized patients with nonpurulent cellulitis, a beta-lactam (cefazolin) may be considered initially, switching to MRSA-active therapy only if no clinical response 1.

Critical Practice Points

Avoid rifampin: Never use as monotherapy or adjunctive therapy for cellulitis—no proven benefit and promotes resistance 1

Route of administration: Recent evidence shows oral antibiotics are as effective as IV for similar severity cellulitis, with no difference in outcomes at days 10 and 30 4, 6. The preference for IV therapy often reflects clinician bias rather than superior efficacy 4.

Duration: Five days is adequate for most cases; extending beyond this provides no additional benefit unless clinical response is inadequate 1, 4, 6

Special populations:

• TMP-SMX is pregnancy category C/D (avoid third trimester and infants <2 months) 1
• Tetracyclines are contraindicated in children <8 years and pregnancy 1
• Elderly patients on TMP-SMX with renal insufficiency or renin-angiotensin inhibitors risk hyperkalemia 1

Address predisposing factors: Examine interdigital toe spaces for tinea pedis, treat underlying edema/lymphedema, and optimize wound care to prevent recurrence 1